{"id":"5-fluorouracile","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"15-40","effect":"Mucositis"},{"rate":"10-30","effect":"Diarrhea"},{"rate":"10-25","effect":"Nausea and vomiting"},{"rate":"5-20","effect":"Hand-foot syndrome"},{"rate":"5-15","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"5-FU is converted intracellularly to active metabolites that inhibit thymidylate synthase, blocking dTMP synthesis and thus DNA replication. Additionally, the drug is incorporated into both RNA and DNA, causing direct damage and triggering apoptosis in rapidly dividing cells. This multi-target mechanism makes it effective against a broad range of solid tumors.","oneSentence":"5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:18.871Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Breast cancer"},{"name":"Gastric cancer"},{"name":"Head and neck cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT03795311","phase":"PHASE1, PHASE2","title":"Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2018-11-07","conditions":"Colorectal Cancer","enrollment":32},{"nctId":"NCT03874026","phase":"PHASE2","title":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2019-09-05","conditions":"Colorectal Cancer, ADCC","enrollment":34},{"nctId":"NCT05476796","phase":"PHASE2","title":"Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-06-23","conditions":"Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":118},{"nctId":"NCT02842580","phase":"PHASE2","title":"De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-09","conditions":"Colorectal Neoplasms","enrollment":21},{"nctId":"NCT04392479","phase":"PHASE3","title":"TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.","status":"UNKNOWN","sponsor":"Hôpital Franco-Britannique-Fondation Cognacq-Jay","startDate":"2020-09-02","conditions":"Cancer Colorectal, Metastasis","enrollment":202},{"nctId":"NCT02484677","phase":"PHASE4","title":"Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2015-07-15","conditions":"Patients With Head and Neck Cancer (ORL)","enrollment":12},{"nctId":"NCT02268695","phase":"PHASE2","title":"Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2014-10-10","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":541},{"nctId":"NCT02143219","phase":"PHASE2","title":"Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2014-07-31","conditions":"Pancreatic Metastatic Cancer, Toxicity","enrollment":72},{"nctId":"NCT02934464","phase":"PHASE3","title":"Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2016-12","conditions":"Stomach Neoplasms","enrollment":280},{"nctId":"NCT01858649","phase":"PHASE2","title":"Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2013-05","conditions":"Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT02640365","phase":"PHASE1","title":"A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2015-11-18","conditions":"Unresectable Advanced Cancer","enrollment":10},{"nctId":"NCT01858662","phase":"PHASE2","title":"Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2014-01","conditions":"Metastatic Colorectal Cancer","enrollment":4},{"nctId":"NCT01104714","phase":"","title":"Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2010-04","conditions":"Carcinoma, Squamous Cell, Mouth Neoplasms, Oropharyngeal Neoplasms","enrollment":90},{"nctId":"NCT00055679","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Stage I Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2002-08","conditions":"Breast Cancer","enrollment":1512},{"nctId":"NCT00960284","phase":"PHASE2, PHASE3","title":"Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2003-06","conditions":"Pancreatic Cancer","enrollment":102},{"nctId":"NCT00138060","phase":"PHASE4","title":"Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants","status":"COMPLETED","sponsor":"Institut de Recherche Clinique sur les Cancers et le Sang","startDate":"2005-06","conditions":"Metastatic Colorectal Cancer","enrollment":71}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"PARAESTHESIA"},{"count":5,"reaction":"NEUTROPENIA"},{"count":5,"reaction":"RASH"},{"count":5,"reaction":"THROMBOCYTOPENIA"},{"count":4,"reaction":"ERYTHEMA"},{"count":4,"reaction":"INFUSION RELATED REACTION"},{"count":4,"reaction":"PRURITUS"},{"count":4,"reaction":"VOMITING"},{"count":3,"reaction":"ASTHENIA"},{"count":3,"reaction":"HYPERTENSION"}],"_approvalHistory":[],"publicationCount":79,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["5FU"],"phase":"marketed","status":"active","brandName":"5-Fluorouracile","genericName":"5-Fluorouracile","companyName":"Groupe Oncologie Radiotherapie Tete et Cou","companyId":"groupe-oncologie-radiotherapie-tete-et-cou","modality":"Small molecule","firstApprovalDate":"","aiSummary":"5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death. Used for Colorectal cancer, Gastric cancer, Breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}